Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SY-008 Phase Ib MAD Study in Type 2 Diabetes
NCT04345120Phase 1Completed
- Sponsor
- Yabao Pharmaceutical Group Co., Ltd.
- Start
- Jun 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SY-008 in type 2 diabetes mellitus (T2DM), sponsored by Yabao Pharmaceutical Group Co., Ltd. Primary endpoints: Maximum postprandial blood glucose added value at 7 days, Blood glucose AUC in different periods at 7 days and 5 more. Started Jun 2020; status: completed.
02
Drugs
SY-008
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04345120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04345120.